Agreement Between SomaLogic, Inc. and New England Biolabs, Inc. Enables the Use of SOMAmer Technology for the Optimization of Multiple PCR Products
Published: Jul 28, 2011
BOULDER, Colo., and IPSWICH, Mass., July 27, 2011 /PRNewswire/ -- SomaLogic, Inc. and New England Biolabs, Inc. (NEB) announce today that they have entered into an exclusive licensing agreement whereby SomaLogic will provide specific SOMAmers as critical and unique reagents in several current and future NEB nucleic acid amplification and polymerase chain reaction (PCR) products.
SOMAmers are specific protein binding reagents based on chemically modified "aptamers," or short single-stranded nucleic acids. Although SOMAmers have nearly unlimited potential in many different proteomic applications (e.g., biomarker discovery and validation, clinical diagnostics, drug discovery and development), NEB is incorporating specific SOMAmers into their products as reversible inhibitors of thermally active DNA polymerases used in PCR (e.g., NEB's OneTaq Hot Start DNA Polymerase).
"We are delighted that our colleagues at New England Biolabs see the utility of SOMAmers in enhancing and differentiating their outstanding laboratory solutions from their many competitors," said Nebojsa Janjic, Chief Science Officer of SomaLogic. "We look forward to working with them to further explore and apply the distinct advantages of our powerful technology in research laboratory settings."
"There are many opportunities to further enhance the performance of thermally active DNA polymerases in PCR reactions," states Dr. Salvatore Russello, Associate Director of Business Development at NEB. "This agreement is thus of great value to NEB, and is already being used to improve the application of DNA polymerases, such as OneTaq Hot Start."
Terms of the agreement were not disclosed.
SomaLogic, Inc., is a privately held biomarker discovery and clinical diagnostics company based in Boulder, Colorado. The company's mission is to use its proprietary Slow Off-rate Modified Aptamer ("SOMAmer") technology to develop enhanced protein analysis tools and reagents for the life sciences community, to facilitate biomarker discovery and validation, and to develop and commercialize clinical diagnostic products that will improve the delivery of healthcare by offering timely and accurate diagnostic information to physicians and their patients. Further information about SomaLogic can be found at www.somalogic.com.
About New England Biolabs
Established in the mid 1970's, New England Biolabs, Inc. is the industry leader in the discovery and production of enzymes for molecular biology applications and now offers the largest selection of recombinant and native enzymes for genomic research. NEB continues to expand its product offerings into areas related to PCR, gene expression, sample preparation for next generation sequencing, cellular analysis, epigenetics and RNA analysis. Additionally, NEB is focused on strengthening alliances that enable new technologies to reach key market sectors. New England Biolabs is a privately held company, headquartered in Ipswich, MA and has extensive worldwide distribution through a network of exclusive distributors, agents and six subsidiaries located in Canada, China, France, Germany, Japan and the UK. For more information about New England Biolabs visit www.neb.com.
SOURCE New England Biolabs, Inc.